METHOCARBAMOL

Methocarbamol Adverse Events Reported to the FDA Over Time

How are Methocarbamol adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Methocarbamol, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Methocarbamol is flagged as the suspect drug causing the adverse event.

Most Common Methocarbamol Adverse Events Reported to the FDA

What are the most common Methocarbamol adverse events reported to the FDA?

Cardiac Arrest	38 (3.41%)
Completed Suicide	36 (3.23%)
Respiratory Arrest	34 (3.05%)
Cardio-respiratory Arrest	32 (2.88%)
Convulsion	24 (2.16%)
Amnesia	23 (2.07%)
Chronic Obstructive Pulmonary Disea...	23 (2.07%)
Emphysema	23 (2.07%)
Bedridden	22 (1.98%)
Fibromyalgia	22 (1.98%)
Drug Toxicity	19 (1.71%)
	Show More
Depressed Level Of Consciousness	14 (1.26%)
Multiple Drug Overdose	14 (1.26%)
Asthenia	13 (1.17%)
Fatigue	11 (.99%)
Overdose	11 (.99%)
Poisoning	11 (.99%)
Suicide Attempt	11 (.99%)
Death	10 (.9%)
Drug Ineffective	10 (.9%)
Fall	10 (.9%)
Loss Of Consciousness	10 (.9%)
Confusional State	9 (.81%)
Somnolence	9 (.81%)
Chest Pain	8 (.72%)
Drug Hypersensitivity	8 (.72%)
Headache	8 (.72%)
Pain	8 (.72%)
Pyrexia	8 (.72%)
Condition Aggravated	7 (.63%)
Mental Status Changes	7 (.63%)
Muscle Spasms	7 (.63%)
Psychotic Disorder	7 (.63%)
Chills	6 (.54%)
Cognitive Disorder	6 (.54%)
Drug Interaction	6 (.54%)
Intentional Overdose	6 (.54%)
Myoclonus	6 (.54%)
Nausea	6 (.54%)
Oedema Peripheral	6 (.54%)
Suicidal Ideation	6 (.54%)
Syncope	6 (.54%)
Dizziness	5 (.45%)
Drug Abuse	5 (.45%)
Hyperhidrosis	5 (.45%)
Hypertension	5 (.45%)
Hypotension	5 (.45%)
Inflammation	5 (.45%)
Insomnia	5 (.45%)
Malaise	5 (.45%)
Medication Error	5 (.45%)
Multiple Drug Overdose Accidental	5 (.45%)
Sedation	5 (.45%)
Sepsis	5 (.45%)
Vomiting	5 (.45%)
Abdominal Pain	4 (.36%)
Abnormal Dreams	4 (.36%)
Accidental Overdose	4 (.36%)
Agitation	4 (.36%)
Anaemia	4 (.36%)
Blood Glucose Increased	4 (.36%)
Blood Pressure Increased	4 (.36%)
Drug Abuser	4 (.36%)
Dry Mouth	4 (.36%)
Heart Rate Increased	4 (.36%)
Hilar Lymphadenopathy	4 (.36%)
Hypoxia	4 (.36%)
Intentional Drug Misuse	4 (.36%)
Lung Disorder	4 (.36%)
Multiple Drug Overdose Intentional	4 (.36%)
Pain In Extremity	4 (.36%)
Product Quality Issue	4 (.36%)
Pruritus	4 (.36%)
Rash	4 (.36%)
Thrombocytopenia	4 (.36%)
Alcohol Use	3 (.27%)
Arthralgia	3 (.27%)
Atrial Fibrillation	3 (.27%)
Back Pain	3 (.27%)
Blood Ph Decreased	3 (.27%)
Bradycardia	3 (.27%)
Coma	3 (.27%)
Constipation	3 (.27%)
Depression	3 (.27%)
Dyspepsia	3 (.27%)
Dyspnoea	3 (.27%)
Electrocardiogram Qt Prolonged	3 (.27%)
Erythema	3 (.27%)
Flushing	3 (.27%)
Gait Disturbance	3 (.27%)
Hypoaesthesia	3 (.27%)
Joint Swelling	3 (.27%)
Lethargy	3 (.27%)
Lymphadenopathy Mediastinal	3 (.27%)
Memory Impairment	3 (.27%)
Metabolic Encephalopathy	3 (.27%)
Muscle Rigidity	3 (.27%)
Musculoskeletal Stiffness	3 (.27%)
Myalgia	3 (.27%)
Off Label Use	3 (.27%)
Oliguria	3 (.27%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Methocarbamol, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Methocarbamol is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Methocarbamol

What are the most common Methocarbamol adverse events reported to the FDA?

Cardiac Arrhythmias	84 (7.55%)
Neurological	77 (6.92%)
Medication Errors	60 (5.39%)
Respiratory	56 (5.03%)
Suicidal And Self-injurious Behavio...	54 (4.85%)
Muscle	39 (3.5%)
Lifestyle Issues	36 (3.23%)
Mental Impairment	34 (3.05%)
Chemical Injury And Poisoning	32 (2.88%)
Lower Respiratory Tract Disorders	26 (2.34%)
Gastrointestinal Signs	25 (2.25%)
	Show More
Seizures	25 (2.25%)
Therapeutic And Nontherapeutic Effe...	24 (2.16%)
Bronchial Disorders	23 (2.07%)
Epidermal And Dermal Conditions	18 (1.62%)
Infections - Pathogen Unspecified	18 (1.62%)
Injuries	18 (1.62%)
Cardiac And Vascular Investigations	16 (1.44%)
Psychiatric	16 (1.44%)
Musculoskeletal And Connective Tiss...	15 (1.35%)
Deliria	13 (1.17%)
Fatal Outcomes	12 (1.08%)
Anxiety Disorders	11 (.99%)
Headaches	10 (.9%)
Allergic Conditions	9 (.81%)
Body Temperature Conditions	9 (.81%)
Joint	9 (.81%)
Physical Examination Topics	9 (.81%)
Sleep Disorders	9 (.81%)
Spleen, Lymphatic And Reticulendoth...	9 (.81%)
Gastrointestinal Motility And Defec...	8 (.72%)
Decreased And Nonspecific Blood Pre...	7 (.63%)
Enzyme	7 (.63%)
Metabolic, Nutritional And Blood Ga...	7 (.63%)
Movement Disorders	7 (.63%)
Schizophrenia And Other Psychotic	7 (.63%)
Anemias Nonhemolytic And Marrow Dep...	6 (.54%)
Electrolyte And Fluid Balance Condi...	6 (.54%)
Hematology Investigations	6 (.54%)
Hepatic And Hepatobiliary	6 (.54%)
Ocular Neuromuscular	6 (.54%)
Product Quality Issues	6 (.54%)
Renal Disorders	6 (.54%)
Vascular Hypertensive	6 (.54%)
Angiedema And Urticaria	5 (.45%)
Disturbances In Thinking	5 (.45%)
Hepatobiliary	5 (.45%)
Skin Appendage Conditions	5 (.45%)
Therapeutic Procedures And Supporti...	5 (.45%)
Bacterial Infectious	4 (.36%)
Musculoskeletal And Connective Tiss...	4 (.36%)
Platelet	4 (.36%)
Salivary Gland Conditions	4 (.36%)
Vascular	4 (.36%)
Administration Site Reactions	3 (.27%)
Bone And Joint Injuries	3 (.27%)
Central Nervous System Vascular	3 (.27%)
Changes In Physical Activity	3 (.27%)
Coronary Artery	3 (.27%)
Depressed Mood Disorders	3 (.27%)
Encephalopathies	3 (.27%)
Gastrointestinal Neoplasms Malignan...	3 (.27%)
Musculoskeletal And Soft Tissue Inv...	3 (.27%)
Renal And Urinary Tract Investigati...	3 (.27%)
Skin Vascular Abnormalities	3 (.27%)
Urinary Tract Signs	3 (.27%)
Viral Infectious	3 (.27%)
Water, Electrolyte And Mineral	3 (.27%)
Appetite And General Nutritional	2 (.18%)
Bone Disorders	2 (.18%)
Gastrointestinal Conditions	2 (.18%)
Gastrointestinal Hemorrhages	2 (.18%)
Hematopoietic Neoplasms	2 (.18%)
Myocardial	2 (.18%)
Pleural	2 (.18%)
Procedural And Device Related Injur...	2 (.18%)
Tissue	2 (.18%)
Tongue Conditions	2 (.18%)
Toxicology And Therapeutic Drug Mon...	2 (.18%)
White Blood Cell	2 (.18%)
Acid-base	1 (.09%)
Adrenal Gland	1 (.09%)
Bone And Joint Therapeutic Procedur...	1 (.09%)
Cardiac Disorder Signs	1 (.09%)
Eye	1 (.09%)
Gastrointestinal Inflammatory Condi...	1 (.09%)
Gastrointestinal Stenosis And Obstr...	1 (.09%)
Gastrointestinal Ulceration And Per...	1 (.09%)
Inner Ear And Viiith Cranial Nerve	1 (.09%)
Investigations, Imaging And Histopa...	1 (.09%)
Lipid Analyses	1 (.09%)
Lipid Metabolism	1 (.09%)
Metastases	1 (.09%)
Microbiology And Serology	1 (.09%)
Miscellaneous And Site Unspecified ...	1 (.09%)
Mood Disorders	1 (.09%)
Neuromuscular	1 (.09%)
Ocular Hemorrhages And Vascular	1 (.09%)
Oral Soft Tissue Conditions	1 (.09%)
Peripheral Neuropathies	1 (.09%)
Purine And Pyrimidine Metabolism	1 (.09%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Methocarbamol, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Methocarbamol is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.